Jang Bae Moon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jang Bae Moon has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Deok-Hwan Yang
Department of Hematology‐Oncology Chonnam National University Hwasun Hospital, Chonnam National University Medical School Hwasun Jeollanam‐do Republic of Korea
1 shared publication - Dong Deuk Kwon
Department of Urology, Chonnam National University Medical School, Gwangju, Korea
1 shared publication - Dong-Jin Park
Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School & Hospital, Gwangju, Korea
1 shared publication - Eu Chang Hwang
Department of Urology Chonnam National University Medical School, Chonnam National University Hwasun Hospital Hwasun South Korea
1 shared publication - Ga-Young Song
Department of Hematology-Oncology, Chonnam National University and Hwasun Hospital, Hwasun, Jeollanam-do, Republic of Korea
1 shared publication - Hee-Seung Bom
Department of Nuclear Medicine, Chonnam National University Hwasun Hospital, Hwasun-gun, Republic of Korea
1 shared publication
Latest Publications
- Open Access
Diagnostic Performance of 68Ga-PSMA-11 PET/CT Compared with Multiparametric MRI for Initial Local Staging of Prostate Cancer
Background/Objectives: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) remains insufficient for the initial local staging of prostate cancer (PC). This study aimed to compare the diagnostic accuracy of 68Ga-PSMA-11 PET/CT and multiparametric magnetic resonance imaging (mpMRI) for localised or locally advanced PC. Methods: We retrospectively reviewed patients who underwent preoperative 68Ga-PSMA-11 PET/CT and prostate mpMRI followed by radical prostatectomy (RP) at two tertiary institutions between August 2022 and April 2026. Side-specific PC, extraprostatic extension (EPE) and seminal vesicle invasion (SVI) were assessed using two imaging modalities and compared to pathologic T staging via RP. The diagnostic performance of 68Ga-PSMA-11 PET/CT and mpMRI was investigated. Results: Overall, 440 patients were included. Regarding side-specific PC detection, 68Ga-PSMA-11 PET/CT showed significantly higher sensitivity than mpMRI (72.9% vs. 61.8%, p < 0.001), whereas mpMRI had higher specificity (93.3% vs. 76.7%, p = 0.009). The two modalities showed similar overall discrimination (area under the receiver operating characteristic curve [AUC], 0.748 vs. 0.776, p = 0.323). For EPE, mpMRI had higher sensitivity than 68Ga-PSMA-11 PET/CT (42.3% vs. 7.1%, p < 0.001), whereas 68Ga-PSMA-11 PET/CT had higher specificity (96.1% vs. 84.5%, p < 0.001). Overall performance favoured mpMRI (AUCs, 0.634 vs. 0.516; p < 0.001). For SVI, mpMRI outperformed 68Ga-PSMA-11 PET/CT in sensitivity (48.7% vs. 20.5%, p = 0.002) and overall discrimination (AUC, 0.730 vs. 0.598; p = 0.001), while specificity was comparable (97.3% vs. 99.0%, p = 0.052). Conclusions: 68Ga-PSMA-11 PET/CT shows promise for the initial local staging of PC. The higher sensitivity of 68Ga-PSMA-11 PET/CT for localised PC suggests a potential complementary role in surgical planning. Conversely, in patients with EPE or SVI, mpMRI provides superior diagnostic performance overall.
Open AccessDiagnostic Performance of 68Ga-PSMA-11 PET/CT Compared with Multiparametric MRI for Initial Local Staging of Prostate Cancer
Background/Objectives: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) remains insufficient for the initial local staging of prostate cancer (PC). This study aimed to compare the diagnostic accuracy of 68Ga-PSMA-11 PET/CT and multiparametric magnetic resonance imaging (mpMRI) for localised or locally advanced PC. Methods: We retrospectively reviewed patients who underwent preoperative 68Ga-PSMA-11 PET/CT and prostate mpMRI followed by radical prostatectomy (RP) at two tertiary institutions between August 2022 and April 2026. Side-specific PC, extraprostatic extension (EPE) and seminal vesicle invasion (SVI) were assessed using two imaging modalities and compared to pathologic T staging via RP. The diagnostic performance of 68Ga-PSMA-11 PET/CT and mpMRI was investigated. Results: Overall, 440 patients were included. Regarding side-specific PC detection, 68Ga-PSMA-11 PET/CT showed significantly higher sensitivity than mpMRI (72.9% vs. 61.8%, p < 0.001), whereas mpMRI had higher specificity (93.3% vs. 76.7%, p = 0.009). The two modalities showed similar overall discrimination (area under the receiver operating characteristic curve [AUC], 0.748 vs. 0.776, p = 0.323). For EPE, mpMRI had higher sensitivity than 68Ga-PSMA-11 PET/CT (42.3% vs. 7.1%, p < 0.001), whereas 68Ga-PSMA-11 PET/CT had higher specificity (96.1% vs. 84.5%, p < 0.001). Overall performance favoured mpMRI (AUCs, 0.634 vs. 0.516; p < 0.001). For SVI, mpMRI outperformed 68Ga-PSMA-11 PET/CT in sensitivity (48.7% vs. 20.5%, p = 0.002) and overall discrimination (AUC, 0.730 vs. 0.598; p = 0.001), while specificity was comparable (97.3% vs. 99.0%, p = 0.052). Conclusions: 68Ga-PSMA-11 PET/CT shows promise for the initial local staging of PC. The higher sensitivity of 68Ga-PSMA-11 PET/CT for localised PC suggests a potential complementary role in surgical planning. Conversely, in patients with EPE or SVI, mpMRI provides superior diagnostic performance overall.
- Open Access
- 17 February 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 50 (4) , 281-288
Prognostic Value of 18F-FDG PET in Primary Central Nervous System Lymphoma
Purpose of the Report: The usefulness of brain 18F-FDG PET/CT in primary central nervous system lymphoma (PCNSL) remains underexplored. This study investigated whether early metabolic responses in interim brain FDG PET/CT serve as a prognostic indicator of PCNSL treatment outcomes. Patients and Methods: This prospective study included 53 patients with PCNSL who underwent a high-dose methotrexate–based treatment. Brain FDG PET was performed at diagnosis (baseline PET) and after induction chemotherapy (interim PET), assessing interim PET parameters such as the highest maximum standardized uptake value (hSUVmax), sum of SUVmax (sumSUVmax), highest tumor-to-normal ratio (hTNRmax), sum of TNRmax (sumTNRmax), highest metabolic tumor volume (MTV) (hMTV), and sum of MTV (sumMTV) across all PET-positive lesions. Results: High interim hTNRmax (hazards ratio: 9.76, 95% confidence interval: 1.90–50.11, P = 0.01) was an independently significant predictor of poor progression-free survival in multivariate analysis. Patients with low interim hTNRmax (≤1.0) had a significantly longer median progression-free survival than those with high interim hTNRmax (>1.0) (25.0 vs 3.6 months, P < 0.001). Incorporating interim MRI-based clinical response assessments and hTNRmax allowed the classification of partial response subgroups with markedly different prognoses (P < 0.001). High interim hTNRmax (hazards ratio: 2.76, 95% confidence interval: 1.39–5.48, P = 0.004) was an independently significant predictor of poor overall survival in multivariate analysis. Conclusions: The hTNRmax measurement from interim brain FDG PET scans emerges as an important prognostic marker in PCNSL. These findings underscore the potential of interim FDG PET evaluations to refine response assessments and inform tailored therapeutic strategies.
- 17 February 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 50 (4) , 281-288
Open AccessPrognostic Value of 18F-FDG PET in Primary Central Nervous System Lymphoma
Purpose of the Report: The usefulness of brain 18F-FDG PET/CT in primary central nervous system lymphoma (PCNSL) remains underexplored. This study investigated whether early metabolic responses in interim brain FDG PET/CT serve as a prognostic indicator of PCNSL treatment outcomes. Patients and Methods: This prospective study included 53 patients with PCNSL who underwent a high-dose methotrexate–based treatment. Brain FDG PET was performed at diagnosis (baseline PET) and after induction chemotherapy (interim PET), assessing interim PET parameters such as the highest maximum standardized uptake value (hSUVmax), sum of SUVmax (sumSUVmax), highest tumor-to-normal ratio (hTNRmax), sum of TNRmax (sumTNRmax), highest metabolic tumor volume (MTV) (hMTV), and sum of MTV (sumMTV) across all PET-positive lesions. Results: High interim hTNRmax (hazards ratio: 9.76, 95% confidence interval: 1.90–50.11, P = 0.01) was an independently significant predictor of poor progression-free survival in multivariate analysis. Patients with low interim hTNRmax (≤1.0) had a significantly longer median progression-free survival than those with high interim hTNRmax (>1.0) (25.0 vs 3.6 months, P < 0.001). Incorporating interim MRI-based clinical response assessments and hTNRmax allowed the classification of partial response subgroups with markedly different prognoses (P < 0.001). High interim hTNRmax (hazards ratio: 2.76, 95% confidence interval: 1.39–5.48, P = 0.004) was an independently significant predictor of poor overall survival in multivariate analysis. Conclusions: The hTNRmax measurement from interim brain FDG PET scans emerges as an important prognostic marker in PCNSL. These findings underscore the potential of interim FDG PET evaluations to refine response assessments and inform tailored therapeutic strategies.
- Open Access
- 1 January 2014
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 16 (2) , R88
MicroRNA-155 as a proinflammatory regulator via SHIP-1 down-regulation in acute gouty arthritis
Gout is characterized by episodes of intense joint inflammation in response to intra-articular monosodium urate monohydrate (MSU) crystals. miR-155 is crucial for the proinflammatory activation of human myeloid cells and antigen-driven inflammatory arthritis. The functional role of miR-155 in acute gouty arthritis has not been defined. Therefore, the aim of this study was to examine the role of miR-155 in pathogenesis of acute gouty arthritis.
- 1 January 2014
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 16 (2) , R88
Open AccessMicroRNA-155 as a proinflammatory regulator via SHIP-1 down-regulation in acute gouty arthritis
Gout is characterized by episodes of intense joint inflammation in response to intra-articular monosodium urate monohydrate (MSU) crystals. miR-155 is crucial for the proinflammatory activation of human myeloid cells and antigen-driven inflammatory arthritis. The functional role of miR-155 in acute gouty arthritis has not been defined. Therefore, the aim of this study was to examine the role of miR-155 in pathogenesis of acute gouty arthritis.